drugset / Trial / NCT05347771
Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents
Phase 2
Active not recruiting
240 enrolled
National Institute of Allergy and Infectious Diseases (NIAID)
Childhood Asthma in Urban Settings (CAUSE) · collabRegeneron Pharmaceuticals · collabRho Federal Systems Division, Inc. · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a multi-center, double-blind, placebo-controlled, randomized trial of dupilumab adjunctive therapy for prevention of asthma exacerbations in urban children and adolescents with T2-high exacerbation-prone asthma.
Timeline
- Start
- 2022-05-04
- Primary completion
- 2026-12-31
- Completion
- 2027-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dupilumab | Monoclonal antibody | 100 mg | Subcutaneous |
| Subject | Dupilumab | Monoclonal antibody | 200 mg | Subcutaneous |
| Subject | Dupilumab | Monoclonal antibody | 300 mg | Subcutaneous |